![]() |
|
|
Forward to a colleague |
||
Access Full Stories UK researchers have published results that show that microfluidic devices can provide robust quantitative pharmacological information from low numbers of single cells... Read Product news in brief - week 49 LabTechnologist.com brings you a periodic round up of new product releases from Carl Zeiss SMT, Genetix, Ludesi, Millipore, Nikon, Olympus and Wiley-VCH... Read Genetic 'ID cards' enable meat traceability A new genetic identity test that can be used to confirm the breed and origin of meat from farm animals has been developed to enable complete meat traceability... Read Separating mixtures in an NMR machine Canadian researchers have devised a method of extracting the complete proton NMR (nuclear magnetic resonance) spectra for a component of a mixture without the need for physical separation... Read Luminex offers personalised miRNA panels Luminex has expanded its range of FlexmiR miRNA assays with the addition of user-customisable panels that will enable researchers to study only those miRNAs they are interested in... Read |
||||||||||||||||||
All News Headlines for: December | November | October |
||||||||||||||||||
ZIC®-HILIC Separation of Polar and Hydrophilic Compounds SeQuant is introducing a new ZIC®-HILIC column for ultra-high speed applications. Its potential is illustrated by a complete baseline separation of Oseltamavir (Tamiflu®) from Oseltamavir Carboxylate followed by MS/MS detection in less than 40 seconds... Click Here | ||||||||||||||||||
|
Related Industry News BMS reveals plans to trim the fat Bristol-Myers Squibb (BMS) has finally detailed its plans to trim the fat and save cash, months after first revealing that big changes would be on the cards... Read Abbott cuts jobs, closes plant in Ireland Abbott is to shut its doors on its Galway, Ireland, facility - taking 500 jobs with it - as the market moves into murky waters over the future of vascular stents... Read Combo products need guidelines The combination products market is zooming ahead, requiring the need to address regulatory challenges, an author of a white paper says... Read Morphosys to exit fee-for-service upon Novartis deal Morphosys has landed in the money after scoring a lucrative 10 year antibody development deal with Novartis and as a result, will now place all its eggs in one basket and cut ties with its fee-for-service customers... Read
|
||||||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@LabTechnologist.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||